Skip to content
AnalystLens

Charles River Laboratories International Annual Report, Year Ended Dec 30, 2017

Filing Date
Filed February 13, 2018
Period End
December 30, 2017
Security
CRL
One revenue dollarkept$0.07
In the record · 2016–202610-K1110-Q338-K117

CRL filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 117 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’16Jun ’16
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-K filed February 13, 2018. Cited figures are marked; the original filing is the authoritative source.

Charles River Laboratories International, Inc. describes itself as a full service, early-stage contract research organization (CRO) with three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

In fiscal 2017, total revenue was $1,857.6 milliona, up from $1,681.4 million in 2016, an increase of $176.2 million, or 10.5%, driven mainly by DSA (revenue of $980.0 million, up 17.1%) and Manufacturing ($384.0 million, up 9.5%), while RMS revenue was essentially flat at $493.6 million. Operating income rose to $287.5 million from $237.4 million, and income from continuing operations was $125.6 million, compared with $156.1 million in 2016, reflecting a $104.6 million increase in the income tax provision. The provision included a $78.5 million estimate for the impact of U.S. Tax Reform, and the effective tax rate rose to 57.7% from 30.0%.

The company's balance sheet and cash flow position changed meaningfully during the year. Net cash provided by operating activities was $318.1 millionb, and total debt was $1.1 billion at year end. The company also divested its CDMO business for $75.0 million in February 2017, acquired Brains On-Line in August 2017, and recorded an $18.1 million restructuring charge in the fourth quarter related to the planned closure of its Maryland RMS production facility.

Cash and cash equivalents were $163.8 millionc at December 30, 2017. Looking ahead, the filing discloses a definitive agreement signed February 12, 2018 to acquire MPI Research for an expected preliminary purchase price of approximately $800 million in cash, expected to close early in the second quarter of 2018 and to be reported in the DSA segment.

The company has a commitment for up to $830 milliond under a bridge loan facility to finance the transaction, and the filing notes a termination fee of $48 million, increasing to $56 million under specified circumstances. The company also acquired KWS BioTest in January 2018 for $20.3 million in cash.

Key Highlights

  1. Total revenue reached $1,857.6 million in fiscal 2017, up 10.5% from $1,681.4 million, led by the DSA segment, which grew 17.1% to $980.0 million.
  2. Operating income increased to $287.5 million (15.5% operating margin) from $237.4 million (14.1%) in 2016.
  3. Net income attributable to common shareholders fell to $123.4 million from $154.8 million, mainly due to a $104.6 million increase in income tax provision related to U.S. Tax Reform.
  4. U.S. Tax Reform resulted in a $78.5 million provisional estimate in fiscal 2017, including a $73.5 million one-time transition tax, and the effective tax rate was 57.7% versus 30.0% in 2016.
  5. A definitive agreement to acquire MPI Research was signed February 12, 2018, with a preliminary purchase price of approximately $800 million in cash and a planned $830 million bridge loan commitment.
  6. Total debt was $1.1 billion at December 30, 2017, and management stated it intends to increase debt by approximately $830 million to finance the MPI Research acquisition.
  7. A restructuring plan to close the Maryland RMS production facility before the end of 2018 generated $18.1 million of costs in the fourth quarter of 2017, with additional 2018 costs estimated at $6.5 million to $7.5 million.

Follow one dollar

Of each $1.00 of revenue in FY2017, Charles River Laboratories International kept $0.07.

  1. Revenue$1.86B100.0%
  2. Cost of revenue−$289.7M15.6%
  3. Gross profit$1.57B84.4%
  4. Operating costs−$1.28B68.9%
  5. Operating income$288.3M15.5%
  6. Interest, other & tax−$164.9M8.9%
  7. Net income$123.4M6.6%
Computed from 10-KFY2017filed February 13, 2018Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2017 revenue went

$1.86B
  • Other operating costs: $908.4M, 49% of revenue
  • SG&A: $371.3M, 20% of revenue
  • Cost of revenue: $289.7M, 16% of revenue
  • Net income: $123.4M, 6.6% of revenue
  • Interest, other & tax: $164.9M, 8.9% of revenue

Kept 6.6% as net incomeNet income $123.4M · 6.6%

Full revenue history →

Financial Statements

FY2017 against FY2016

Line itemFY2017FY2016Change
Revenue$1.86B$1.68B+10.5%
Cost of Revenue$289.67M$277.03M+4.6%
Gross Profit$1.57B$1.40B+11.6%
SG&A Expenses$371.27M$364.71M+1.8%
Operating Income$288.28M$237.55M+21.4%
Interest Expense$29.78M$27.71M+7.5%
Net Income$123.36M$154.76M−20.3%
EPS (Basic)$2.60$3.29−21.0%
EPS (Diluted)$2.54$3.23−21.4%
Shares Outstanding (Basic)47.48M47.01M+1.0%
Shares Outstanding (Diluted)48.56M47.96M+1.3%

Frequently Asked Questions

  1. How did Charles River's revenue and profitability change in fiscal 2017?

    Total revenue rose $176.2 million, or 10.5%, to $1,857.6 million, primarily from DSA and Manufacturing growth. Operating income increased to $287.5 million from $237.4 million, but income from continuing operations declined to $125.6 million from $156.1 million because of a higher income tax provision of $171.4 million.

  2. What drove the large increase in income tax expense?

    The provision for income taxes was $171.4 million, up $104.6 million from 2016. The increase was primarily driven by the one-time transition tax on unrepatriated foreign earnings under U.S. Tax Reform, the change in the company's indefinite reinvestment assertion, and a gain on the CDMO divestiture, partially offset by excess tax benefits from stock-based compensation.

  3. What is the MPI Research acquisition and how will it be financed?

    On February 12, 2018, Charles River entered into a definitive agreement to acquire MPI Research, a non-clinical CRO, for a preliminary purchase price of approximately $800 million in cash, expected to close early in the second quarter of 2018. The company expects to finance it through an expansion of its credit facility and cash, and has a commitment for up to $830 million under a bridge loan facility. The business will be reported in the DSA segment.

  4. How is the company's debt position after the fiscal year?

    At December 30, 2017, total debt was $1.1 billion, with a $1.65B Credit Facility outstanding balance of $1,102.3 million. Management stated it intends to increase debt by approximately $830 million in connection with the MPI Research acquisition and is evaluating fixed-rate financing alternatives. The filing also notes a 100-basis point rise in interest rates would increase annual pre-tax interest expense by $11.0 million.

  5. What restructuring actions did the company take in 2017?

    In the fourth quarter of 2017, Charles River committed to close its RMS production facility in Maryland before the end of 2018, consolidate production elsewhere, and reduce workforce at other global RMS facilities. Costs recognized in the fourth quarter were $18.1 million, of which $17.7 million related to asset impairments and accelerated depreciation, with additional costs of $6.5 million to $7.5 million expected in 2018.